Gansu Longshenrongfa Pharmaceutical Industry CO. (300534)
Search documents
中药板块8月4日涨0.42%,陇神戎发领涨,主力资金净流出5.56亿元
Zheng Xing Xing Ye Ri Bao· 2025-08-04 08:30
Market Performance - The Traditional Chinese Medicine (TCM) sector rose by 0.42% on August 4, with Longshen Rongfa leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] Top Gainers in TCM Sector - Longshen Rongfa (300534) closed at 12.09, up 7.18% with a trading volume of 646,800 shares and a turnover of 777 million yuan [1] - Weikang Pharmaceutical (300878) closed at 27.26, up 6.40% with a trading volume of 198,700 shares and a turnover of 513 million yuan [1] - Darentang (600329) closed at 41.20, up 6.30% with a trading volume of 164,600 shares and a turnover of 664 million yuan [1] Top Losers in TCM Sector - Biotech Valley (833266) closed at 12.80, down 8.51% with a trading volume of 215,700 shares and a turnover of 271 million yuan [2] - Datang Pharmaceutical (836433) closed at 8.19, down 4.88% with a trading volume of 204,800 shares and a turnover of 166 million yuan [2] - Huason Pharmaceutical (002907) closed at 20.00, down 3.57% with a trading volume of 390,300 shares and a turnover of 787 million yuan [2] Capital Flow Analysis - The TCM sector experienced a net outflow of 556 million yuan from institutional investors, while retail investors saw a net inflow of 375 million yuan [2] - The net inflow from speculative funds was 181 million yuan [2] Individual Stock Capital Flow - China Resources Sanjiu (000999) had a net inflow of 86.17 million yuan from institutional investors, while retail investors saw a net outflow of 56.84 million yuan [3] - Yabao Pharmaceutical (600351) had a net inflow of 57.28 million yuan from institutional investors, with retail investors experiencing a net outflow of 42.13 million yuan [3] - Tongrentang (600085) had a net inflow of 53.69 million yuan from institutional investors, while retail investors had a net outflow of 58.73 million yuan [3]
A股创新药概念股局部反弹,翰宇药业午后直线拉升涨超10%,海辰药业、阳光诺和、广生堂涨超10%,福源医药、万泽股份涨停,陇神戎发、京新药业、常山药业、舒泰神等跟涨。
news flash· 2025-08-04 05:10
A股创新药概念股局部反弹,翰宇药业午后直线拉升涨超10%,海辰药业、阳光诺和、广生堂涨超 10%,福源医药、万泽股份涨停,陇神戎发、京新药业、常山药业、舒泰神等跟涨。 ...
中药股探底回升,陇神戎发一度涨超10%
Mei Ri Jing Ji Xin Wen· 2025-08-04 02:19
每经AI快讯,8月4日,中药股探底回升,陇神戎发一度涨超10%,奇正藏药此前涨停,粤万年青、新天 药业、盘龙药业、佛慈制药等跟涨。 (文章来源:每日经济新闻) ...
陇神戎发(300534)8月1日主力资金净流入3493.46万元
Sou Hu Cai Jing· 2025-08-01 09:25
Company Performance - As of August 1, 2025, Longshen Rongfa (300534) closed at 11.28 CNY, up 4.16% with a turnover rate of 16.28% and a trading volume of 491,600 shares, amounting to 554 million CNY [1] - The latest quarterly report shows total revenue of 289 million CNY, a year-on-year increase of 13.52%, and a net profit attributable to shareholders of 24.21 million CNY, up 9.18% year-on-year [1] - The company's non-recurring net profit reached 26.92 million CNY, reflecting a year-on-year growth of 26.88% [1] - Financial ratios include a current ratio of 1.430, a quick ratio of 1.160, and a debt-to-asset ratio of 46.50% [1] Capital Flow - On the reporting day, the net inflow of main funds was 34.93 million CNY, accounting for 6.3% of the total transaction amount [1] - Large orders saw a net inflow of 34.64 million CNY, representing 6.25% of the transaction amount, while small orders experienced a net outflow of 62.55 million CNY, which is 11.28% of the transaction amount [1] Company Background - Gansu Longshen Rongfa Pharmaceutical Co., Ltd. was established in 2002 and is located in Lanzhou, primarily engaged in the pharmaceutical manufacturing industry [2] - The company has a registered capital of 303.345 million CNY and has made investments in five enterprises, participated in 2,052 bidding projects, and holds 17 trademarks and 46 patents [2]
A股中药股逆势上涨,生物谷涨25%,维康药业20CM涨停,新光药业涨13%,大唐药业涨11%,太龙药业、贵州百灵涨停
Ge Long Hui· 2025-08-01 06:05
(责任编辑:宋政 HN002) 格隆汇8月1日|A股市场中药股逆势上涨,其中,生物谷涨近25%,维康药业20CM涨停,新光药业 (300519)涨13%,大唐药业涨近11%,天目药业(600671)、新天药业(002873)、太龙药业(600222)、奇正 藏药(002287)、贵州百灵(002424)10CM涨停,众生药业(002317)涨超8%,亚宝药业(600351)、沃华医药 (002107)涨超6%。 | 代码 | 名称 | 涨幅% ↓ | 总市值 | 年初至今涨幅%。 | | --- | --- | --- | --- | --- | | 833266 | 生物谷 | 24.91 | 17.60亿 | 51.12 | | 300878 | 维康药业 | 20.00 | 37.10亿 | 71.51 | | 300519 | 新光药业 | 13.04 | 31.76亿 | 52.71 | | 836433 | 大唐药业 | 10.76 | 22.14亿 | 42.65 | | 600671 | 天目药业 | 10.03 | 18.71亿 | 74.94 | | 002873 | 新天药业 | 10. ...
A股中药股逆势上涨,太龙药业、贵州百灵等多股涨停
Ge Long Hui A P P· 2025-08-01 05:51
MACD金叉信号形成,这些股涨势不错! 格隆汇8月1日|A股市场中药股逆势上涨,其中,生物谷(维权)涨近25%,维康药业(维权)20CM 涨停,新光药业涨13%,大唐药业涨近11%,天目药业、新天药业、太龙药业、奇正藏药、贵州百灵 (维权)10CM涨停,众生药业涨超8%,亚宝药业、沃华医药(维权)涨超6%。 | 代码 | 名称 | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | | 833266 | 生物谷 | 24.91 | 17.60亿 | 51.12 | | 300878 | 维康药业 | 20.00 | 37.10亿 | 71.51 | | 300519 | 新光药业 | 13.04 | 31.76 乙 | 52.71 | | 836433 | 大唐药业 | 10.76 | 22.14亿 | 42.65 | | 600671 | 天目药业 | 10.03 | 18.71亿 | 74.94 | | 002873 | 新天药业 | 10.03 | 29.19亿 | 27.68 | | 600222 | 太龙药业 | 10.00 | 39.14 ...
中药板块逆势拉升 天目药业等多股涨停
Mei Ri Jing Ji Xin Wen· 2025-08-01 05:50
(文章来源:每日经济新闻) 每经AI快讯,8月1日,午后中药板块持续逆势拉升,天目药业、华森制药涨停,生物谷一度触及30%涨 停,新光药业、大唐药业涨超10%,亚宝药业、沃华医药、陇神戎发、粤万年青等跟涨。 ...
A股中药板块持续逆势拉升,天目药业、华森制药涨停,生物谷一度触及30cm涨停,新光药业、大唐药业涨超10%,亚宝药业、沃华医药、陇神戎发、粤万年青等跟涨。
news flash· 2025-08-01 05:44
Group 1 - The A-share traditional Chinese medicine sector is experiencing a significant upward trend, with companies like Tianmu Pharmaceutical and Huasen Pharmaceutical hitting the daily limit increase [1] - Biotech Valley reached a peak of 30cm limit increase, indicating strong market interest and investor confidence [1] - Other companies such as New Light Pharmaceutical and Datang Pharmaceutical saw increases of over 10%, reflecting a broader positive movement in the sector [1] Group 2 - Additional companies including Yabao Pharmaceutical, Wohua Pharmaceutical, Longshen Rongfa, and Guangdong Wannianqing also showed gains, contributing to the overall bullish sentiment in the traditional Chinese medicine market [1]
陇神戎发:公司坚持以市场为导向
Zheng Quan Ri Bao Wang· 2025-07-31 12:01
证券日报网讯陇神戎发(300534)7月31日在互动平台回答投资者提问时表示,公司坚持以市场为导 向,强化内外部协同创新,深耕主打品种二次开发的同时,积极开展新产品的研发工作。 ...